Puma Biotechnology (PBYI) Change in Account Payables (2011 - 2026)

Puma Biotechnology has reported Change in Account Payables for 16 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 501.55% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (up 172.84% YoY), and the FY2025 full-year result was -$453000.0, up 67.17% from the prior year.
• Change in Account Payables for Q1 2026 stood at $3.1 million, up from -$1.3 million in the prior quarter.
• The five-year high for Change in Account Payables was $5.1 million in Q3 2022, with the low at -$8.5 million in Q4 2022.
• Historically, Change in Account Payables has averaged -$176941.2 across 5 years, with a median of $517000.0 in 2025.
• The largest YoY upside for Change in Account Payables was 671.28% in 2024 against a maximum downside of 209.41% in 2024.
• Puma Biotechnology's Change in Account Payables stood at -$8.5 million in 2022, then surged by 121.54% to $1.8 million in 2023, then slumped by 209.41% to -$2.0 million in 2024, then jumped by 33.5% to -$1.3 million in 2025, then jumped by 333.83% to $3.1 million in 2026.
• The last three Change in Account Payables figures came in at $3.1 million (Q1 2026), -$1.3 million (Q4 2025), and $962000.0 (Q3 2025), per Business Quant data.